Lapatinib in Combination With Radiation Diminishes Tumor Regrowth in HER2+ and Basal-Like/EGFR+ Breast Tumor Xenografts

Authors
Publication date
1 January 2010
Publisher
Doi
    View on PubMed

    Abstract

    To determine whether lapatinib, a dual epidermal growth factor receptor (EGFR)/HER2 kinase inhibitor, can radiosensitize EGFR+ or HER2+ breast cancer xenografts

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Carolina Digital Repository

      redirect
      oaicdr.lib.unc.edu:6m311w47b
      Last time updated on 24/11/2020